When was transplantation of human Limbal Stem Cells (LSCs) cultured on human Amniotic Membrane (AM) first used in humans to treat Limbal Stem Cell Deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Transplantation of Human Limbal Stem Cells on Amniotic Membrane for Limbal Stem Cell Deficiency

The first transplantation of human Limbal Stem Cells (LSCs) cultured on human Amniotic Membrane (AM) for treating Limbal Stem Cell Deficiency was performed in 1997, as documented in scientific literature.1

Historical Development

The technique of using cultured limbal epithelial cells on amniotic membrane emerged as a promising treatment for limbal stem cell deficiency in the late 1990s. This approach represented a significant advancement in treating conditions that previously had limited therapeutic options.

Key developments include:

  • 1997: First application of cultured limbal epithelial cells on amniotic membrane for treating limbal stem cell deficiency 1
  • 2002: Early clinical results published showing transplantation of cultivated corneal/limbal epithelium on human amniotic membrane for severe limbal deficiency 2
  • 2010: Further refinement of techniques for culture and transplantation of human limbal stem cells 3

Clinical Applications

Limbal stem cell deficiency (LSCD) can result from various conditions including:

  • Stevens-Johnson syndrome
  • Ocular cicatricial pemphigoid
  • Chemical burns
  • Other conditions causing limbal stem cell dysfunction 2

These conditions can lead to:

  • Conjunctival scarring and shrinkage
  • Symblepharon formation
  • Corneal scarring and neovascularization
  • Severe vision loss 4

Cultivation Techniques

The cultivation of limbal epithelial cells on amniotic membrane involves several approaches:

  • Explant culture technique: Using human amniotic membrane as the culture substrate 1
  • Culture media options:
    • Complex media containing fetal bovine serum
    • Media with human serum as single growth supplement 5
    • Various protocols using different growth additives

Clinical Outcomes

Early studies showed mixed results:

  • In a 2002 study, epithelium regenerated and covered the ocular surface in 61.5% of cases initially
  • Long-term success (corneal epithelialization) was achieved in 46.2% of cases
  • Complications included corneal perforation and infectious keratitis 2

More recent approaches have shown improved outcomes:

  • Development of biomimetic scaffolds like decellularized human limbus
  • Enhanced biocompatibility and integration 6
  • Better long-term clinical outcomes, particularly for patients with severe damage

Current Status and Future Directions

Current research focuses on:

  • Optimizing culture conditions
  • Developing better scaffolds
  • Improving long-term outcomes
  • Expanding applications to various forms of limbal stem cell deficiency

Clinical Considerations

When considering limbal stem cell transplantation:

  • Comprehensive evaluation of the extent of limbal stem cell deficiency
  • Assessment of underlying cause
  • Consideration of bilateral vs. unilateral disease
  • Evaluation of potential for autologous vs. allogeneic transplantation
  • Management of potential complications including rejection and infection

The technique continues to evolve with ongoing research into optimal cultivation methods, scaffolds, and transplantation techniques to improve outcomes for patients with this challenging condition.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.